Pharmaceutical News

RSS

Imprimis, Advanced Dosage sign license agreement for proprietary compounded ophthalmic formulations

Imprimis Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced that it has entered into a license agreement with Advanced Dosage Forms, Inc. to expand Imprimis' proprietary ophthalmic injectable and combination topical compounded formulations into Canada. Under the agreement, the licensee has the rights to formulate, market and sell these formulations across Canada.

12 Aug 2015

Findings may lead to more accurate diagnostic test, possible vaccine for oral and genital herpes

Findings from a pair of new studies could speed up the development of a universally accurate diagnostic test for human herpes simplex viruses, according to researchers at Johns Hopkins and Harvard universities and the National Institutes of Health.

12 Aug 2015

Study finds no added benefit for insulin degludec and liraglutide in type 2 diabetes

The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an injection in addition to other blood-glucose lowering drugs when these alone or in combination with basal insulin are insufficient to lower blood glucose levels.

12 Aug 2015

Janssen signs license agreement with Alligator Bioscience for immuno-oncology antibody

Janssen Biotech, Inc., one of the Janssen pharmaceutical companies of Johnson & Johnson announced today an exclusive, worldwide license agreement with Alligator Bioscience AB for ADC-1013, an immuno-oncology agent currently in Phase 1 clinical studies.

12 Aug 2015

IQWiG dossier assessment finds no added benefit for vortioxetine in depression

Vortioxetine (trade name: Brintellix) has been approved since December 2013 for the treatment of depression in adults, but did not become actually available before May 2015. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this drug offers an added benefit over the appropriate comparator therapy. Such an added benefit cannot be derived from the dossier because it contained no data evaluable for the assessment.

12 Aug 2015

Novel combination therapy effective at treating patients with skin metastases

In findings never before seen in melanoma, a novel combination therapy was found to be highly effective at treating patients with skin metastases, new research from UC Davis has shown.

12 Aug 2015

New review points to most promising areas for liposomes' further development

An international group of scientists, including Vladimir Chupin, head of the Biophysics Section at MIPT, and Vladimir Torchilin (Northeastern University, the USA), one of the world's leading experts in pharmacology, recently presented a review of liposomes, microscopic capsules widely used all over the world in the development of new drugs.

11 Aug 2015

New VA study demonstrates cardiovascular benefits of testosterone replacement therapy

A Veterans Affairs database study of more than 83,000 patients found that men whose low testosterone was restored to normal through gels, patches, or injections had a lower risk of heart attack, stroke, or death from any cause, versus similar men who were not treated.

11 Aug 2015

McMaster research shows benefits of corticosteroid therapy for patients with pneumonia

McMaster University research, published online today by the Annals of Internal Medicine, has demonstrated the benefits of corticosteroid therapy for one of the most common serious medical conditions.

11 Aug 2015

Researchers apply new approach to make improved nasal spray flu vaccine

Johns Hopkins Bloomberg School of Public Health researchers say they have developed a method that could make a nasal spray flu vaccine effective for those under two and over 49 - two groups for which the vaccine is not approved.

11 Aug 2015

Impax sells U.S. rights to Daraprim brand for $55 million to Turing Pharmaceuticals

Impax Laboratories, Inc. today announced that it has sold its U.S. rights to the Daraprim brand to Turing Pharmaceuticals AG for approximately $55 million.

10 Aug 2015

Mylan announces launch of Lidocaine Patch 5% in the U.S.

Mylan N.V. today announced the U.S. launch of its Lidocaine Patch 5%, which is the generic version of Endo Pharmaceutical's Lidoderm. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for relief of pain associated with post-herpetic neuralgia.

10 Aug 2015

Turing Pharmaceuticals acquires rights to market Daraprim (pyrimethamine) in the U.S.

Turing Pharmaceuticals AG today announced that it has acquired the exclusive rights to market Daraprim (pyrimethamine) in the U.S. from Impax Laboratories, Inc. The acquisition by Turing is part of a strategic effort focused on treatments for toxoplasmosis and other serious infectious diseases. The company also announced plans to invest in the development of new drug candidates for toxoplasmosis.

10 Aug 2015

TNK Therapeutics acquires multiple preclinical and clinical stage CAR-T immunotherapy programs

Sorrento Therapeutics, Inc. announced today that its wholly-owned subsidiary, TNK Therapeutics, Inc., has acquired multiple preclinical and clinical stage chimeric antigen receptor (CAR)-T immunotherapy programs as well as underlying CAR-T technology through the acquisition of two privately-held biotechnology companies.

10 Aug 2015

Global Pharmaceutical Contract Manufacturing market estimated to reach $84 billion in 2020

Mordor Intelligence releases their report on the Global Pharmaceutical Contract Manufacturing market is segmented by Dose Formulation type (Solid Dose Formulation, Liquid Dose Formulation, Injectable Dose Formulation - By Geographical Region (North America, Europe, Latin America, APAC, Middle East & Africa) - Drivers, Restraints, Vendor Profiles, Global Market Size, Forecasts & Analysis (2015-2020).

10 Aug 2015

IQWiG examines added benefit of dasabuvir and ombitasvir/paritaprevir/ritonavir in different patient groups

Dasabuvir (trade name Exviera) and the fixed-dose drug combination ombitasvir/paritaprevir/ritonavir (trade name Viekirax) have been available since January 2015 for the treatment of adults with chronic hepatitis C infection. The German Institute for Quality and Efficiency in Health Care had examined their added benefit in a dossier assessment completed in April 2015.

7 Aug 2015

BMC partners with RIH, CVS to support pharmacy-based naloxone rescue kits to help combat opioid addiction, overdose

Boston Medical Center has received a $1.3 million grant from the Agency for Healthcare Research and Quality to support a demonstration project of pharmacy-based naloxone rescue kits to help reduce opioid addiction and overdose death in two New England States: Massachusetts and Rhode Island.

7 Aug 2015

Experts discuss ways to encourage appropriate use of epinephrine for all severe allergic reactions

There are times when emergency physicians can't be 100 percent sure a person is suffering from a severe allergic reaction, known as anaphylaxis, and may hesitate to use epinephrine. A new article says when in doubt - administer the epinephrine.

7 Aug 2015

Newcastle University awarded £5M for drug development research

Cancer Research UK's Drug Discovery Committee has today (Friday) awarded Newcastle University's Northern Institute of Cancer Research £5M to bring more cancer drugs to clinical trials.

7 Aug 2015

Scientists develop technique to identify Viagra and other hidden ingredients in dietary supplements

To lose weight, boost energy or soothe nerves, many consumers turn to dietary supplements. But some of these products contain undeclared substances. To protect consumers from taking something without their knowledge, scientists have developed a technique to determine what secret ingredients could be lurking in these supplements.

6 Aug 2015

Pharmaceutical News

Imprimis, Advanced Dosage sign license agreement for proprietary compounded ophthalmic formulations

Findings may lead to more accurate diagnostic test, possible vaccine for oral and genital herpes

Study finds no added benefit for insulin degludec and liraglutide in type 2 diabetes

Janssen signs license agreement with Alligator Bioscience for immuno-oncology antibody

IQWiG dossier assessment finds no added benefit for vortioxetine in depression

Novel combination therapy effective at treating patients with skin metastases

New review points to most promising areas for liposomes' further development

New VA study demonstrates cardiovascular benefits of testosterone replacement therapy

McMaster research shows benefits of corticosteroid therapy for patients with pneumonia

Researchers apply new approach to make improved nasal spray flu vaccine

Impax sells U.S. rights to Daraprim brand for $55 million to Turing Pharmaceuticals

Mylan announces launch of Lidocaine Patch 5% in the U.S.

Turing Pharmaceuticals acquires rights to market Daraprim (pyrimethamine) in the U.S.

TNK Therapeutics acquires multiple preclinical and clinical stage CAR-T immunotherapy programs

Global Pharmaceutical Contract Manufacturing market estimated to reach $84 billion in 2020

IQWiG examines added benefit of dasabuvir and ombitasvir/paritaprevir/ritonavir in different patient groups

BMC partners with RIH, CVS to support pharmacy-based naloxone rescue kits to help combat opioid addiction, overdose

Experts discuss ways to encourage appropriate use of epinephrine for all severe allergic reactions

Newcastle University awarded £5M for drug development research

Scientists develop technique to identify Viagra and other hidden ingredients in dietary supplements

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News